Compare Micron Technology, Inc. (MU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Micron Technology, Inc. trades at $878.38 (market cap $1.08T), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Micron Technology, Inc. is far larger — about 221.3× Travere Therapeutics Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 49 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MU | TVTX | |
|---|---|---|
Market Cap | $1.08T | $4.88B |
Volume | 28,906,235 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $1.21K | $67.52 |
52-Week Low | $191.94 | $26.79 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $1.04T | $5.01B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) is trading at $914.13, down 7.57% today, following strong recent performance. The stock shows robust fundamentals with a P/E of 12.82, net income margin of 63.8%, and consistent earnings beats. Technical indicators show a bullish moving average signal despite today's pullback, with support at $978. The company benefits from strong AI-driven memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus at 82.85% buy ratings and $1,590 price target. Key opportunities include sustained AI memory demand and reduced cyclicality through long-term contracts. Risks include potential growth deceleration in 2028 and market volatility. The stock's current valuation appears reasonable given strong profitability and growth trajectory.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
